Application of liquid biopsy based on circulating tumor DNA in the monitoring of pseudoprogression in tumor immunotherapy / 肿瘤研究与临床

ABSTRACT

As widely-used immunotherapy has brought therapeutic benefits to cancer patients, some problems begin to come, such as pseudoprogression which has posed a major challenge for clinicians to manage patients receiving novel drugs. If pseudoprogression is mistaken for the progression of the disease, the immunotherapy is stopped, which may lead patients to lose the treatment opportunity. Liquid biopsies based on circulating tumor DNA (ctDNA) play a key role in the evaluation of therapeutic efficacy and drug-resistance mechanism of tumor immunotherapy. This article reviews the potential application of ctDNA in the identification of pseudoprogressio for patients after tumor immunotherapy.